Globus Medical, Inc. (GMED)
NYSE: GMED · IEX Real-Time Price · USD
51.27
+0.02 (0.04%)
Apr 23, 2024, 4:00 PM EDT - Market closed
Globus Medical Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Globus Medical stock have an average target of 66.33, with a low estimate of 53 and a high estimate of 86. The average target predicts an increase of 29.37% from the current stock price of 51.27.
Analyst Consensus: Buy
* Price targets were last updated on Mar 18, 2024.
Analyst Ratings
The average analyst rating for Globus Medical stock from 10 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Buy | 1 | 1 | 2 | 2 | 2 | 2 |
| Hold | 7 | 7 | 7 | 4 | 4 | 4 |
| Sell | 1 | 1 | 1 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 13 | 9 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Hold → Strong Buy Upgrades $60 | Hold → Strong Buy | Upgrades | $60 | +17.03% | Mar 18, 2024 |
| Stifel | Stifel | Strong Buy Maintains $61 → $64 | Strong Buy | Maintains | $61 → $64 | +24.83% | Feb 21, 2024 |
| Truist Securities | Truist Securities | Hold Maintains $58 → $60 | Hold | Maintains | $58 → $60 | +17.03% | Feb 21, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $70 | Buy | Reiterates | $70 | +36.53% | Jan 11, 2024 |
| Truist Securities | Truist Securities | Hold Maintains $53 → $58 | Hold | Maintains | $53 → $58 | +13.13% | Dec 22, 2023 |
Financial Forecast
Revenue This Year
2.51B
from 1.57B
Increased by 60.28%
Revenue Next Year
2.70B
from 2.51B
Increased by 7.56%
EPS This Year
2.75
from 1.07
Increased by 156.54%
EPS Next Year
3.35
from 2.75
Increased by 22.15%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 2.6B | 2.8B | 3.2B | 3.4B | 3.6B |
| Avg | 2.5B | 2.7B | 2.9B | 3.1B | 3.5B |
| Low | 2.4B | 2.6B | 2.7B | 2.8B | 3.4B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 66.1% | 13.1% | 17.1% | 15.1% | 16.6% |
| Avg | 60.3% | 7.6% | 8.2% | 5.9% | 13.3% |
| Low | 52.4% | 1.6% | 1.4% | -5.2% | 8.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 2.85 | 4.10 | 4.55 | 5.00 | 5.23 |
| Avg | 2.75 | 3.35 | 4.02 | 4.63 | 5.08 |
| Low | 2.63 | 3.00 | 3.31 | 4.23 | 4.88 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 166.8% | 49.2% | 35.6% | 24.5% | 12.9% |
| Avg | 156.5% | 22.2% | 19.8% | 15.3% | 9.7% |
| Low | 145.5% | 9.2% | -1.2% | 5.4% | 5.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.